Dihydroquercetin (DHQ) is a bioflavonoid with high antioxidant, capillary-protective, and anti-inflammatory activity. DHQ has previously been used for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection and is currently considered a potential regulator of oxidative stress as part of COVID-19 multipurpose therapy. DHQ has a high safety profile but low bioavailability that limits its use. Innovative techniques (liposomization, crystal engineering, etc.) can be used to increase its bioavailability.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831168 | PMC |
| http://dx.doi.org/10.1007/s11094-022-02548-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and pharmacological evaluation of natural product diphyllin derivatives against head and neck squamous cell carcinoma.
Eur J Med Chem
December 2024
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, 200011, China; Digital Diagnosis and Treatment Innovation Center for Cancer, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address:
Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors, but clinical drug treatments are limited. The natural product diphyllin was identified as a lead compound suppressing the proliferation of HNSCC cells through phenotypic screening of natural product library. However, further developments of diphyllin as an anti-HNSCC agent were restricted by the weak bioactivity and poor metabolic stability.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Background: γ-Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease (AD). GSMs selectively reduce amyloidogenic long Aβ peptides (e.g.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.
Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.
View Article and Find Full Text PDFPotential Risks from Cannabis-Infused Beverages: A Critical Review.
Cannabis
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton and McMaster University.
Unlabelled: Although Canada legalized cannabis beverages in 2019, most available research on acute cannabis intoxication derives from dried flower and edible products. The distinct bioavailability and pharmacokinetic properties of phytocannabinoids ingested from beverages, however, contribute to significantly different acute and long-term effects that need to be better understood to ensure consumer safety.
Objective: This review investigates existing cannabis beverage literature, with a particular focus on acute intoxication effects.
Inclusion Complex of Nimodipine with Sulfobutylether-β-cyclodextrin: Preparation, Characterization, In Vitro and In Vivo Evaluation.
AAPS PharmSciTech
January 2025
Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
Nimodipine (NIMO) is used to treat ischemic nerve injury from subarachnoid hemorrhage (SAH), but its low aqueous solubility limits clinical safety and bioavailability. This study aims to improve NIMO's solubility by preparing inclusion complexes with sulfobutylether-β-cyclodextrin (SBE-β-CD), reducing the limitations of Nimotop injection, including vascular irritation, toxicity, and poor dilution stability. The NIMO-SBE-β-CD inclusion complex (NIMO-CD) was characterized in both liquid and solid states through phase solubility studies and methods including DSC, FT-IR, XRD, and SEM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!